Sociedad Americana de Hirudoterapia

Agjencia Kombëtare e Barnave dhe Pajisjeve Mjekësore — Republika e Shqipërisë

AKBPM · Albania · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Albania's National Agency of Medicines and Medical Devices — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Albania
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Albanian Law No. 105/2014 on Medicinal Products and Pharmaceutical Service, as amended
  • Albanian national medical device regulatory framework (progressively aligning with EU MDR 2017/745 in connection with EU accession negotiations)

Prescriber Requirements

  • Albanian Order of Physicians–registered doctor — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

AKBPM registration as applicable; Albanian-language labelling. Standard cold-chain conditions.

Import/Export Rules

AKBPM and Ministry of Agriculture and Rural Development clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Albanian Mandatory Healthcare Insurance Fund (FSDKSh) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Albanian regulation is progressively converging toward the EU acquis as part of the EU accession process; whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.